abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

这页面没有简体中文版本,现以English显示

文章

2007年2月16日

作者:
Novartis

Novartis seeking clarity in Indian patent laws, a critical incentive for long-term R&D investments into better medicines for patients

A hearing began today in an Indian court to gain clarity on the status of the country’s laws regarding the protection of intellectual property and the granting of patents, which are critical to helping patients by creating incentives for long-term R&D investments into new and better medicines. The hearing taking place in Chennai is part of efforts by Novartis...to gain a patent for its life-saving medicine Glivec.